Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 4/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705285 | 0.88 | CAPN1 (0.33) | ARG1CAPN1HPGDTSHRNPSR1 | |
| SCHEMBL3635784 | 0.82 | CAPN1 (0.39) | ARG1CAPN1ARG2 | |
| SCHEMBL4620561 | 0.76 | AAK1 (0.38) | — | |
| SCHEMBL4801806 | 0.76 | CAPN1 (0.46) | CAPN1 | |
| SCHEMBL5705300 | 0.75 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL4623099 | 0.75 | CAPN1 (0.45) | CAPN1 | |
| SCHEMBL4806210 | 0.74 | CAPN1 (0.46) | CAPN1 | |
| SCHEMBL4807064 | 0.73 | CAPN1 (0.31) | CAPN1 | |
| SCHEMBL4623776 | 0.73 | ALPI (0.41) | CAPN1 | |
| SCHEMBL7516940 | 0.73 | CAPN1 (0.39) | CAPN1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465721-B2 | 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| EP-1701974-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-09-20 | — | — | EP | disclosed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
| WO-2005056551-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | CAPN2, CAPN1, CAPNS1 | ARG1 2512/4885CAPN1 2/4885DPP4 728/4885 |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | ARG1 491/4885CAPN1 1/4885DPP4 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.